MENU
DSGN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Design Therapeutics (DSGN) Ownership - Who owns Design Therapeutics?

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations... Show more

Profile

Industry
N/A
Address
6005 Hidden Valley Road
Phone
+1 858 293-4900
Employees
54
Web
https://www.designtx.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
833.8M
P/E Ratio
N/A
Total Cash
222.82M
Projected Growth
N/A
Total Debt
2.73M
Revenue
N/A
Risk (Beta)
1.79
Dividend Yield
N/A
Total Cash/Share
3.57
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
View a ticker or compare two or three
DSGN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Details
Industry
N/A
Address
6005 Hidden Valley Road
Phone
+1 858 293-4900
Employees
54
Web
https://www.designtx.com